1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,760 | 0,795 | 15.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 07.05. | Barinthus Biotherapeutics plc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | Barinthus Biotherapeutics plc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.03. | Barinthus Biotherapeutics plc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 20.03. | Barinthus Biotherapeutics Plc Full Year Loss Narrows | - | RTTNews | ||
| 20.03. | Barinthus Biotherapeutics plc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.03. | Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments | 824 | GlobeNewswire (Europe) | Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000)... ► Artikel lesen | |
| 06.03. | Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 | 234 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About... ► Artikel lesen | |
| 10.01. | Barinthus Bio's UK COO, CFO To Leave, Plans To Cut 65% Headcount To Expand Cash Runway | - | RTTNews | ||
| 10.01. | Barinthus Bio shifts focus, cuts workforce to extend cash runway | 1 | Investing.com | ||
| 10.01. | Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update | 391 | GlobeNewswire (Europe) | Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending... ► Artikel lesen | |
| 10.01. | Barinthus Biotherapeutics plc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.24 | Barinthus Biotherapeutics: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer | 6 | GlobeNewswire (USA) | ||
| 25.11.24 | Barinthus Biotherapeutics plc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.11.24 | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | 378 | GlobeNewswire (Europe) | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
| 15.11.24 | Barinthus Biotherapeutics: Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion | 177 | GlobeNewswire (Europe) | Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United... ► Artikel lesen | |
| 06.11.24 | Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results | 149 | GlobeNewswire (Europe) | OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that... ► Artikel lesen | |
| 01.10.24 | Barinthus Biotherapeutics: Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer | 119 | GlobeNewswire (Europe) | Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update... ► Artikel lesen | |
| 24.09.24 | Barinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease | 329 | GlobeNewswire (Europe) | Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which... ► Artikel lesen | |
| 21.06.24 | Pre-market Movers: Sarepta Therapeutics, Kaival Brands, Barinthus Biotherapeutics, Solid Biosciences, Molecular Partners | 685 | AFX News | FOSTER CITY (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.05 A.M. ET).In the Green Sarepta Therapeutics, Inc. (SRPT) is up over 40%... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,80 | +0,36 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| MEDIGENE | 0,120 | +2,13 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| CUREVAC | 3,094 | +0,72 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| QIAGEN | 37,615 | +0,36 % | ANALYSE-FLASH: UBS belässt Qiagen auf 'Neutral' - Ziel 48 Dollar | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| MODERNA | 21,100 | -0,21 % | Leichter Wertverlust bei der Moderna-Aktie (21,7192 €) | Die Aktie von Moderna notiert am Mittwoch ein wenig leichter. Die Aktie kostete zuletzt 24,34 US-Dollar. An der Börse liegt der Anteilsschein von Moderna derzeit im Minus. Das Wertpapier verbilligte... ► Artikel lesen | |
| AMGEN | 243,10 | +0,10 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| NOVAVAX | 5,607 | -0,55 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| BIOGEN | 109,30 | -1,18 % | Goldman Sachs maintains Biogen buy rating, $196 target | ||
| CRISPR THERAPEUTICS | 32,600 | 0,00 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| PALATIN TECHNOLOGIES | 0,100 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 520,40 | -0,54 % | Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit | ||
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | 0,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,750 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,629 | -0,82 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen |
Das Unternehmen BARINTHUS BIOTHERAPEUTICS PLC ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,035 (+4,49 %) liegt der Kurs bei 0,815 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BARINTHUS BIOTHERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.